CVRx Inc. (CVRX)
NASDAQ: CVRXHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CVRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $14.27M
- EPS (TTM)
- -$2.00
- Dividend yield
- None
- 52-week range
- 0.497 – 10.28
- Day range
- 0.4972 – 0.569
- Volume / Avg
- 519.86K / 744.45K
- Beta
- —
- Shares outstanding
- 28.49M
52-week range
CVRX stock today
CVRx (CVRX) closed at $0.501 on Nov 20, down 5.99% (-$0.0319), versus the S&P 500's 3.70% decline. Shares are 95.1% below their 52-week high of $10.28, set on Nov 25, 2025 and 0.8% above the 52-week low of $0.497, near the bottom of the past year's range. CVRX is down 92.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 94.9%.
CVRx has posted a net loss over the last twelve months (EPS of -$2.00), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About CVRx
Company profileCVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Kevin Hykes
- Headquarters
- Minneapolis, MN
- Employees
- 223
- IPO year
- 2021
- Website
- barostim.com
Financial highlights
Full financialsIn fiscal 2025, CVRx generated $56.7 million in revenue, up 10.4% from fiscal 2024, its 5th consecutive year of revenue growth. CVRx reported a net loss of $53.3 million, compared with a loss of $60.0 million a year earlier. Gross margin was 85.3% (up from 83.8%) and operating margin -90.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $56.65M | $51.29M | $39.30M | $22.47M | $13.04M |
| Growth | +10.45% | +30.53% | +74.89% | +72.36% | +115.36% |
| Net income | $-53.31M | $-59.97M | $-41.20M | $-41.43M | $-43.08M |
| EPS (diluted) | $-2.04 | $-2.65 | $-1.99 | $-2.02 | $-4.16 |
Analyst forecast
ForecastConsensus (7 analysts)
none
Avg. price target
$4.58+814.17%
- Strong buy 0
- Buy 3
- Hold 3
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.49 vs $-0.49
- Surprise
- 0.00%
CVRX news
All CVRX news- ROSEN, TRUSTED INVESTOR COUNSEL, Encourages CVRx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CVRXBusiness Insider
- ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages CVRx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CVRXBusiness Insider
- CVRx to Participate at the Piper Sandler 38th Annual Healthcare ConferenceGlobeNewswire
- CVRX INVESTOR ALERT: Securities Class Action Filed, Hagens Berman Urges CVRx, Inc. Investors with Substantial Losses to Contact Firm Ahead of January 8, 2027 Lead Plaintiff DeadlinePR Newswire
- HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx, Inc. (CVRX) Investors with Substantial Losses to Contact Firm, Securities Class Action FiledPR Newswire
- SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against CVRx, Inc. (NASDAQ: CVRX) -- Investors Who Suffered Losses Are Encouraged to Contact the Firm.PR Newswire
- HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx, Inc. (CVRX) Investors with Substantial Losses to Contact Firm, Securities Class Action FiledPR Newswire
- CVRX INVESTOR ALERT: Securities Class Action Filed, Hagens Berman Urges CVRx, Inc. Investors with Substantial Losses to Contact Firm Ahead of January 8, 2027 Lead Plaintiff DeadlinePR Newswire
CVRx peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DRIODarioHealth Corp. | 1.32 | -8.33% | $14.90M | vs CVRX |
| CTSOCytosorbents Corporation | 4.16 | -18.91% | $13.12M | vs CVRX |
| SNWVSANUWAVE Health Inc. | 1.50 | -5.66% | $12.90M | vs CVRX |
| MODDModular Medical Inc. | 1.68 | -11.81% | $16.36M | vs CVRX |
| RVPRetractable Technologies Inc. | 0.558 | -6.84% | $16.70M | vs CVRX |
| BEATHeartbeam Inc. | 0.2751 | -10.94% | $17.42M | vs CVRX |
| GUTSFractyl Health Inc. | 0.82 | -14.16% | $10.88M | vs CVRX |
| FEMYFemasys Inc. | 1.24 | 0.00% | $10.73M | vs CVRX |
Indexes, lists and sector
CVRx stock FAQ
What is CVRx's stock price today?
CVRX last traded at $0.501 as of Nov 20, 4:00 PM EST, down 5.99% on the day. Prices are delayed at least 15 minutes.
Who is CVRx's CEO?
Mr. Kevin Hykes is the chief executive officer of CVRx Inc., which has about 223 employees.
What is the CVRX 52-week high?
The 52-week high for CVRX is $10.28 and the 52-week low is $0.497. The stock is currently 95.1% below its high.